AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.1974
+0.0053 (2.76%)
Aug 24, 2026, 4:00 PM EDT - Market closed
AEON Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3.43 | 3.01 | 0.01 | 5.16 | 9.75 | 5.13 |
Cash & Short-Term Investments | 3.43 | 3.01 | 0.01 | 5.16 | 9.75 | 5.13 |
Cash Growth | -59.34% | 23023.08% | -99.75% | -47.08% | 90.05% | -74.57% |
Prepaid Expenses | 0.56 | 0.39 | 1.58 | 1.06 | 0.09 | 0.03 |
Total Current Assets | 3.99 | 3.4 | 1.59 | 6.22 | 9.84 | 5.15 |
Property, Plant & Equipment | 1.05 | 1.21 | 1.52 | 0.59 | 0.91 | 0.92 |
Other Long-Term Assets | 0.86 | 0.95 | 0.03 | 0.03 | 0.03 | 0.36 |
Total Assets | 5.91 | 5.56 | 3.14 | 6.85 | 10.78 | 6.44 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.7 | 0.94 | 5.91 | 3.39 | 7.81 | 1.19 |
Accrued Expenses | 4.38 | 5.7 | 8.12 | 9.38 | 3.65 | 4.01 |
Current Portion of Long-Term Debt | - | - | - | - | 70.87 | 15.6 |
Current Portion of Leases | 0.26 | 0.25 | 0.12 | 0.28 | 0.26 | - |
Total Current Liabilities | 7.34 | 6.9 | 14.15 | 13.05 | 82.57 | 20.8 |
Long-Term Debt | 1.76 | 34.6 | 11.69 | - | 60.43 | 70.76 |
Long-Term Leases | 0.76 | 0.89 | 1.15 | - | 0.24 | 0.52 |
Other Long-Term Liabilities | 11.42 | 18.2 | 4.73 | 146.84 | - | 0.22 |
Total Liabilities | 21.27 | 60.59 | 31.71 | 159.89 | 143.24 | 92.31 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0 | 0 | 0.01 | 0.01 |
Additional Paid-In Capital | 468.4 | 415.78 | 403.02 | 381.26 | 187.35 | 187.35 |
Retained Earnings | -483.77 | -470.82 | -431.6 | -473.6 | -474.84 | -422.28 |
Treasury Stock | - | - | - | - | -0.02 | -0.02 |
Comprehensive Income & Other | - | - | - | -60.71 | - | - |
Total Common Equity | -15.36 | -55.03 | -28.57 | -153.04 | -287.5 | -234.94 |
Minority Interest | - | - | - | - | 17.09 | 11.12 |
Shareholders' Equity | -15.36 | -55.03 | -28.57 | -153.04 | -132.46 | -85.88 |
Total Liabilities & Equity | 5.91 | 5.56 | 3.14 | 6.85 | 10.78 | 6.44 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.78 | 35.75 | 12.96 | 0.28 | 131.79 | 86.89 |
Net Cash (Debt) | 0.66 | -32.74 | -12.94 | 4.88 | -122.05 | -81.76 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | 0.02 | -3.30 | -22.47 | 0.06 | -63.29 | -46.63 |
Filing Date Shares Outstanding | 49.88 | 25.3 | 10.53 | 0.55 | 1.93 | 1.93 |
Total Common Shares Outstanding | 26.31 | 12.11 | 0.56 | 0.52 | 1.93 | 1.93 |
Working Capital | -3.35 | -3.5 | -12.56 | -6.83 | -72.74 | -15.65 |
Book Value Per Share | -0.58 | -4.55 | -51.43 | -296.54 | -149.11 | -121.85 |
Tangible Book Value | -15.36 | -55.03 | -28.57 | -153.04 | -287.5 | -234.94 |
Tangible Book Value Per Share | -0.58 | -4.55 | -51.43 | -296.54 | -149.11 | -121.85 |
Machinery | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.13 |
Leasehold Improvements | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |